Trial · NCT05827159
Emergency Department-Initiated Medications for Alcohol Use Disorder
NCT05827159, Phase 3, Recruiting, Yale University
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Emergency Department-Initiated Medications for Alcohol Use Disorder. Trials, record NCT05827159. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05827159
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Emergency Department-Initiated Medications for Alcohol Use Disorder
- NCT number
- NCT05827159
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 240 participants, estimated
- Lead sponsor
- Yale University
- Conditions
- Alcohol Use Disorder
- Interventions
- Naltrexone Pill, Naltrexone Injection, Brief Negotiation Interview, Gabapentin Pill
- First posted
- 2023-04-24
- Last updated
- 2026-07-21
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Participation in AUD Treatment on Day 30 post-randomization | 30 days post enrollment | The proportions of participants participating in AUD treatment on day 30 post enrollment in SBIRT and SBIRT+EDMAUD groups. |
| Secondary | Days of heavy alcohol drinking | 30 days post ED visit | The number of heavy alcohol drinking days during the 30 days prior and during 30 days post the ED index visit. This outcome will be based on self-report using the timeline follow-back (TLFB) method. A day of heavy alcohol drinking is defined by the NIAAA criteria as: for men, consuming more than 4 drinks on any day; for women, consuming more than 3 drinks on any day. |
| Secondary | AUD Treatment Linkage | up to 7 days post ED visit | The proportion of participants that initiate AUD treatment within 7 days post ED visit with providers to which they were referred during the ED visit |
| Secondary | Alcohol craving | up to 7 days post enrollment | Daily intensity of alcohol craving measured on a visual analog scale of 0 to 100. |
| Secondary | Alcohol withdrawal symptoms | up to 7 days post enrollment | Daily intensity of alcohol withdrawal measured on a visual analog scale of 0 to 100. |
| Secondary | Daily naltrexone medication adherence | up to 7 days post enrollment | Number of oral naltrexone doses taken in the past 24 hours for 7 days post enrollment of those initiated on oral naltrexone in the SBIRT+ED- MAUD arm. |
| Secondary | Daily gabapentin medication adherence | up to 7 days post enrollment | Number of gabapentin doses taken in the past 24 hours of those in the SBIRT+ED- MAUD arm. |
| Secondary | Treatment linkage | 7 days | • Proportion of patients in each of the two study arms initiating outpatient AUD treatment within 7 days post the ED visit with providers to which they were referred during the ED visit. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01AA030568 | Emergency Department-Initiated Medications for Alcohol Use Disorder | HAWK, KATHRYN | YALE UNIVERSITY | NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM | 2023 to 2025 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05827159
GET https://conductscience.org/api/trials/v1/NCT05827159/registered